Twist Bio Q4

 — Record revenue of $313.0 million in Fiscal 2024; Increase of 28% over $245.1 million in Fiscal 2023 —

 — Record revenue of $84.7 million in Q4FY24; Increase of 27% over $66.9 million in Q4FY23, 7th consecutive quarter of sequential growth —

 — Gross margin of 45.1% in Q4FY24; Improvement of 8.5 margin points versus 36.6% in 4QFY23 —

 — Expect revenue in the range of $367 million to $377 million for full year Fiscal 2025; expect 50% gross margin for 4QFY25 —

Fiscal 2025 Financial Guidance The following statements are based on Twist’s current expectations for fiscal 2025. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below. For the full fiscal year 2025, Twist expects: • Total revenue is expected to be in the range of $367 million to $377 million, growth of 17 to 20 percent year over year, including: ◦ SynBio revenue of $142 to $146 million, growth of 15 to 18 percent ◦ NGS revenue of $204 to $209 million, growth of 20 to 24 percent ◦ Biopharma revenue of $21 to $22 million, growth of 5 to 8 percent

Gross margin is projected to be approximately 48% for fiscal 2025 with quarterly sequential improvements and 4QFY25 gross margin of 50% • Adjusted EBITDA of approximately $(60) to $(65) million for fiscal 2025

 For the first quarter, Twist expects: • Total revenue of approximately $87 million ◦ SynBio revenue of approximately $34 million, growth of 26% year over year ◦ NGS revenue of approximately $48 million, growth of 22% year over year ◦ Biopharma revenue of approximately $5 million ◦ Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025

Conference Call Information 

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

https://investors.twistbioscience.com/static-files/996f83be-ead3-4b9b-bdf6-22a0c39a7810